MMED vs PODD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PODD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MMED and PODD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MMED and PODD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

MiniMed Group is Medtronic's former Diabetes business, headquartered in Northridge, California, with about 8,000 employees and products sold in about 80 countries. It makes automated insulin delivery systems (the MiniMed 780G, and since 2026 the smaller MiniMed Flex), MiniMed Go smart insulin pens, Simplera continuous glucose monitors, and sells the Instinct sensor made by Abbott, all tied together by its own algorithms and app. CEO Que Dallara leads the company.

Full MMED guide

Insulet Corporation sells one thing extremely well. The Omnipod is a small adhesive pod worn on the body that holds insulin and delivers it without tubing, controlled by a phone app or a handheld. The current generation, Omnipod 5, is an automated insulin delivery system: it reads a continuous glucose monitor (Dexcom G7 or Abbott's FreeStyle Libre) and adjusts basal insulin automatically. The pods are disposable and replaced every three days, so the business is a classic razor-and-blade model where each new user converts into a predictable multi-year consumable stream. Insulet also distributes most of its US volume through the pharmacy channel rather than durable medical equipment, which lowers the friction of getting a patient started and has been a structural advantage over tubed competitors. A small drug delivery segment supplies pod technology to a pharmaceutical partner, but it is under ~2% of revenue and shrinking by design.

Full PODD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MMED drivers: A full US product cycle; International growth engine.
• PODD drivers: Installed base compounding through pods; International expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. For PODD, type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MMED if you believe its drivers more; PODD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MMED and PODD guides.

MMED. At about 1.5 times sales, MiniMed trades at a steep discount to faster-growing, profitable diabetes-device peers, a gap that reflects its GAAP losses, its recent US share losses and the overhang from Medtronic's exit. On forward earnings the multiple is about 25x. The 15 covering analysts rate it a buy with a mean target near $25, and Rothschild & Co Redburn initiated at buy with a $30 target on October 13, 2026.

PODD. Insulet guided full-year 2026 revenue to roughly $3.2-3.3 billion with constant-currency growth of ~20-22%, trimmed from ~21-23%, and cut US Omnipod growth to ~17-19% while raising international to ~30-32%. The cut was small in dollars but changed the narrative: the shares fell about 20% on August 5, 2026 and, at about $142 in mid-October, remain down about 13% over three months and 55% over a year against a 52-week high of ~$355. At roughly 18x forward earnings the stock prices in materially slower growth than it did a year earlier; consensus for Q3, due November 4, is about $1.59 of EPS on ~$833 million of revenue.

Headline figures (approximate, October 2026): MMED shows revenue (ttm) ~$3.2 billion; latest quarter up ~17% year over year, gross / operating margin ~57% / ~0.5%, net income (ttm) ~-$314 million; EPS about -$1.53, p/e (forward) ~25x (forward EPS ~$0.69); PODD shows revenue (ttm) ~$3.05B, q2 2026 revenue ~$802M, up ~23.5% year over year, adjusted gross margin (q2 2026) ~72.9% (GAAP gross margin TTM ~71%), net income / eps (ttm, gaap) ~$375M / ~$5.34.

MMED and PODD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MMED and PODD exposure against your real portfolio. It is not an investment adviser.